Known as Slim Initiative for Genomic Medication.
It will leverage the Broad Institute’s expertise and capabilities in the most advanced technology in genomic sequencing. The project also involves working out of Mexican experts beneath the leadership of the National Institute of Genomic Medicine of the Mexican Secretariat of Wellness, the leading institution in genomic analysis in Latin America. The results of this research will help accelerate both the prevention of disease along with the advancement of improved therapies in Mexico and beyond.The findings might explain why cells in a tumor have therefore many genetic mutations, but could also be bad news for cancer remedies that target a specific gene controlling cancer malignancy. The study was led by Dr. Lawrence Loeb, professor of pathology and biochemistry at the University of Washington College of Medicine in Seattle. Most types of cancers are believed to begin with a random genetic mutation that makes a normal cell go horribly awry. That is accompanied by mutations, which endow the malignancy cells with properties permitting them to grow without normal handles to become a tumor. These mutated genes would be targets for chemotherapy. But Loeb had another idea that he originally hatched a long time ago – imagine if the tumor cells changed somehow, and became much more likely to mutate? These ‘mutator’ cells would develop harmful genetic mutations at a much faster rate than regular cells, which might account for the high number of mutations seen in tumor cells.